L Nagy1, Á Kovács1, B Bódi1, E T Pásztor1, G Á Fülöp1, A Tóth1, I Édes1, Z Papp1. 1. Division of Clinical Physiology, Institute of Cardiology, Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Abstract
BACKGROUND AND PURPOSE: Omecamtiv mecarbil (OM) is a novel cardiac myosin activator drug for inotropic support in systolic heart failure. Here we have assessed the concentration-dependent mechanical effects of OM in permeabilized cardiomyocyte-sized preparations and single skeletal muscle fibres of Wistar-Kyoto rats under isometric conditions. EXPERIMENTAL APPROACHES: Ca2+ -dependent active force production (Factive ), its Ca2+ sensitivity (pCa50 ), the kinetic characteristics of Ca2+ -regulated activation and relaxation, and Ca2+ -independent passive force (Fpassive ) were monitored in Triton X-100-skinned preparations with and without OM (3nM-10 μM). KEY RESULTS: In permeabilized cardiomyocytes, OM increased the Ca2+ sensitivity of force production (ΔpCa50 : 0.11 or 0.34 at 0.1 or 1 μM respectively). The concentration-response relationship of the Ca2+ sensitization was bell-shaped, with maximal effects at 0.3-1 μM OM (EC50 : 0.08 ± 0.01 μM). The kinetics of force development and relaxation slowed progressively with increasing OM concentration. Moreover, OM increased Fpassive in the cardiomyocytes with an apparent EC50 value of 0.26 ± 0.11 μM. OM-evoked effects in the diaphragm muscle fibres with intrinsically slow kinetics were largely similar to those in cardiomyocytes, while they were less apparent in muscle fibres with fast kinetics. CONCLUSIONS AND IMPLICATIONS: OM acted as a Ca2+ -sensitizing agent with a downstream mechanism of action in both cardiomyocytes and diaphragm muscle fibres. The mechanism of action of OM is connected to slowed activation-relaxation kinetics and at higher OM concentrations increased Fpassive production.
BACKGROUND AND PURPOSE:Omecamtiv mecarbil (OM) is a novel cardiac myosin activator drug for inotropic support in systolic heart failure. Here we have assessed the concentration-dependent mechanical effects of OM in permeabilized cardiomyocyte-sized preparations and single skeletal muscle fibres of Wistar-Kyoto rats under isometric conditions. EXPERIMENTAL APPROACHES: Ca2+ -dependent active force production (Factive ), its Ca2+ sensitivity (pCa50 ), the kinetic characteristics of Ca2+ -regulated activation and relaxation, and Ca2+ -independent passive force (Fpassive ) were monitored in Triton X-100-skinned preparations with and without OM (3nM-10 μM). KEY RESULTS: In permeabilized cardiomyocytes, OM increased the Ca2+ sensitivity of force production (ΔpCa50 : 0.11 or 0.34 at 0.1 or 1 μM respectively). The concentration-response relationship of the Ca2+ sensitization was bell-shaped, with maximal effects at 0.3-1 μM OM (EC50 : 0.08 ± 0.01 μM). The kinetics of force development and relaxation slowed progressively with increasing OM concentration. Moreover, OM increased Fpassive in the cardiomyocytes with an apparent EC50 value of 0.26 ± 0.11 μM. OM-evoked effects in the diaphragm muscle fibres with intrinsically slow kinetics were largely similar to those in cardiomyocytes, while they were less apparent in muscle fibres with fast kinetics. CONCLUSIONS AND IMPLICATIONS: OM acted as a Ca2+ -sensitizing agent with a downstream mechanism of action in both cardiomyocytes and diaphragm muscle fibres. The mechanism of action of OM is connected to slowed activation-relaxation kinetics and at higher OM concentrations increased Fpassive production.
Authors: Dóra Bodnár; Nikolett Geyer; Olga Ruzsnavszky; Tamás Oláh; Bence Hegyi; Mónika Sztretye; János Fodor; Beatrix Dienes; Ágnes Balogh; Zoltán Papp; László Szabó; Géza Müller; László Csernoch; Péter Szentesi Journal: J Physiol Date: 2014-01-20 Impact factor: 5.182
Authors: John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff Journal: Lancet Date: 2011-08-20 Impact factor: 79.321
Authors: J van der Velden; Z Papp; R Zaremba; N M Boontje; J W de Jong; V J Owen; P B J Burton; P Goldmann; K Jaquet; G J M Stienen Journal: Cardiovasc Res Date: 2003-01 Impact factor: 10.787
Authors: Anja M Swenson; Wanjian Tang; Cheavar A Blair; Christopher M Fetrow; William C Unrath; Michael J Previs; Kenneth S Campbell; Christopher M Yengo Journal: J Biol Chem Date: 2017-01-12 Impact factor: 5.157
Authors: Alexandre J S Ribeiro; Olivier Schwab; Mohammad A Mandegar; Yen-Sin Ang; Bruce R Conklin; Deepak Srivastava; Beth L Pruitt Journal: Circ Res Date: 2017-04-11 Impact factor: 17.367
Authors: Sarah R Clippinger; Paige E Cloonan; Lina Greenberg; Melanie Ernst; W Tom Stump; Michael J Greenberg Journal: Proc Natl Acad Sci U S A Date: 2019-08-19 Impact factor: 11.205
Authors: Joseph D Powers; Chen-Ching Yuan; Kimberly J McCabe; Jason D Murray; Matthew Carter Childers; Galina V Flint; Farid Moussavi-Harami; Saffie Mohran; Romi Castillo; Carla Zuzek; Weikang Ma; Valerie Daggett; Andrew D McCulloch; Thomas C Irving; Michael Regnier Journal: Proc Natl Acad Sci U S A Date: 2019-05-20 Impact factor: 11.205
Authors: Balázs Horváth; Norbert Szentandrássy; Roland Veress; János Almássy; János Magyar; Tamás Bányász; Attila Tóth; Zoltán Papp; Péter P Nánási Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-09-22 Impact factor: 3.000